Extract
Bronchiectasis is a chronic and often progressive disease, which frequently is associated with significant symptom burden, requiring intensive treatment. Regardless of the multiple potential underlying aetiologies, the vicious cycle of airway inflammation, structural airway damage, impaired mucus clearance and airway pathogen acquisition is the crucial pathogenic pathway for the progression of disease [1].
Abstract
Patients with clinically significant bronchiectasis featuring an eosinophilic inflammatory endotype who were treated with add-on mepolizumab or benralizumab showed a significant improvement of FEV1, symptom burden and quality of life http://bit.ly/2AZvBLm
Footnotes
Conflict of interest: J. Rademacher reports grants and personal fees from Bayer Healthcare, Insmed and Grifols, personal fees from MSD Sharp and Dohme, AstraZeneca and Chiesi, outside the submitted work.
Conflict of interest: S. Konwert has nothing to disclose.
Conflict of interest: J. Fuge has nothing to disclose.
Conflict of interest: S. Dettmer has nothing to disclose.
Conflict of interest: T. Welte reports personal fees for advisory board work and lectures from AstraZeneca, GSK, Grifols, Insmed, Bayer and Novartis, during the conduct of the study; personal fees for advisory board work and lectures from Boehringer and Pfizer, outside the submitted work.
Conflict of interest: F.C. Ringshausen reports grants, personal fees and other from Bayer Healthcare, Insmed Germany and Novartis, grants and personal fees from Grifols, personal fees from MSD Sharp and Dohme, AstraZeneca Boehringer Ingelheim and Vortex, personal fees and other from Chiesi and Gilead, grants from Polyphor, grants and other from InfectoPharm, other from Abbott, Pfizer, Oxycare, Heinen and Löwenstein, MSD, Vertex, Parion, Cetaxsys, Corbus, GSK, PARI, APOSAN and Zambon, outside the submitted work.
- Received February 14, 2019.
- Accepted October 5, 2019.
- Copyright ©ERS 2020